Chemotherapy and immunotherapy of colorectal cancer

Buyse M, Zeleniuch-Jacquotte A, Chalmers T C: Adjuvant therapy of colorectal cancer: why we still do not know?JAMA 259, 3571 (1988). Heidelberg C: Fluorinated pyrimidines, a new class of tumor inhibitory compound.Nature 179, 663 (1957). Moertel C G: Progress and hope in the treatment of gastrointestinal cancer., in Fortner J G and Rhoads J E (eds):Accomplishments in Cancer Research., pp. 295–317. Philadelphia (1987). Gastrointestinal Tumor Study Group: Adjuvant therapy of colon cancer — results of a prospectively randomized trial.N Engl J Med 312, 1465 (1985). Mansour E, Ryan L, Lerner Het al.: Lack of effectiveness of 5-FU-methyl CCNU as compared to 5-FU for adjuvant therapy in colon cancer.Proc Am Soc Clin Oncol 8, 115 (1989). Panettierre F J, Goodman P J, Constanzi J Jet al.: Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group study.J Clin Oncol 6, 947 (1988). Higgins G A Jr, Amadeo J H, McElhinney Jet al.: Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel.Cancer 53, 1 (1984). Abdi E A, Harbora D, Hanson Jet al.: Adjuvant chemoimmuno- and immunotherapy in stage B2 and C colorectal cancer.Proc Am Soc Clin Oncol 6, 93 (1987). Wolmark N, Fisher B, Rockette Het al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.J Natn Cancer Inst 80, 30 (1988). Taylor J, Machin D, Mulleet Met al.: A randomized controlled study of adjuvant portal vein cytotoxic perfusion in colorectal cancer.Br J Surg 72, 359 (1984). Verhaegen H, Decree J, De Cock Wet al.: Levami- sole therapy in patients with colorectal cancer, in Terry W D and Rosenberg S A (eds):Immunotherapy of Human Cancer, pp. 225–229. New York, Elsevier (1982). Cirigos M A, Amery W K: Combined levamisole therapy: an overview of its protective effects, inImmunotherapy of Human Cancer, pp. 181–195. New York, Raven Press (1978). Renoux G: The general immunopharmacology of levamisole.Drugs 20, 89 (1980). Laurie J A, Moertel C G, Fleming T R et al.: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-fluorouracil. A study of the North Central Cancer Treatment Group (NCCTG) and the Mayo Clinic.J Clin Oncol 7, 1447 (1989). Moertel C G, Fleming T H, MacDonald J Set al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.N Engl J Med 322, 352 (1990). Buyse M: Update of published international trials of adjuvant therapy in colorectal cancer. Abstract, EORTC Symp on Advances in Gastrointestinal Tract Cancer Research and Treatment, Strasbourg, p. 4, Nov. 15–17 (1989). Mayer R J: Does adjuvant therapy work in colon cancer?N Engl J Med 322, 399 (1990). The efficacy and the Group C status of levamisole plus 5-fluorouracil for patients with Dukes’ C colon cancer. National Cancer Institute (press release on Levamisole), Bethesda, Maryland 20892 (USA), September 26 (1989). Petrelli N, Herrera L, Rustum Jet al.: A prospective radomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.J Clin Oncol 5, 1559 (1987). Doroshaw J H, Bertrand M, Multhaufs Pet al.: Prospective randomized trial comparing 5-FU versus 5-FU and high doses folinic acid for treatment of advanced colorectal cancer.Proc Am Soc Clin Oncol 6, 96 (1987). Erlichman C, Fine S, Wong Aet al.: A randomized trial of 5-fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.J Clin Oncol 6, 469 (1988). Petrelli N, Madejewicz S, Rustum Y, Herrera L, Creaven P, Plager J, Solomon J, Mittelman A: Combination chemotherapy of cisplatium and 5- fluorouracil for advanced colorectal adenocarcinoma.Cancer Chemother Pharmacol 23, 57 (1989). Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham D L, Fisher E R, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N, Jochimsen P: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP Protocol C-01.J Natn Cancer Inst 80, 30 (1988). Robinson E, Haim N, Bartal A, Mohilever J, Mekori T: Adjuvant radiochemoimmunotherapy in colorectal cancer: results of a randomized study and review of the literature.Int J Immunother 1, 23 (1986). Panettiere F J, Goodman P J, Costanzi J J, Cruz A B Jr, Vaitkevicius V K, McCracken J D, Brownlee R W, Laufman L, Stephens R L, Bonnet J, Bottomley R, Rivkin S, Fletcher W, Oishi N, Chen T T: Adjuvant therapy in large bowel adenocarcinoma: Long-term results of a Southwest oncology group study.J clin Oncol 6, 947 (1988). Hoover H C Jr, Surdyke M, Dangel R B, Peters L C, Hanna M G Jr: Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine.Cancer Res 44, 1671 (1984). Hoover H C, Surdyke M G, Brandhorst J S, Peters L C, Hanna M G: Five-year follow-up of a controlled trial of active specific immunotherapy in colorectal cancer. Abstract.Proc ASCO 9, 106 (1990). Wunderlich M, Schiessel R, Rainer H, Rauhs R, Kovats E, Schemper M, Dittrich Ch, Micksche M, Sedlacek H H: Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure.Br J Surg (Suppl), S107 (1985). Clark P I, Slevin M L, Reznek R H, Niederle N, Kurschel E, Lundell G, Cedermark B, Fallenius A, Blomgren H, Öhman U, Silferswärd C, Theve N O, Wrigley P F M: Two randomized phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (Trial 1) and in combination with 5- fluorouracil (Trial 2) in advanced colorectal cancer.Int J Colored Dis 2, 26 (1987). Krown S E, Mintzer D, Cunningham-Rundles S, Niedzwiecki D, Krim M, Einzig A I, Gabrilove J L, Shurgot B, GessulaJ: High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.Cancer Treat Rep 71, 39 (1987). Lillis P K, Brown T D, Beougher K, Koeller J., Marcus S G, Von Hoff D D: Phase II trial of recombinant beta interferon in advanced colorectal cancer.Cancer Treat Rep 71, 965 (1987). Eggermont A M, Weimar W, Tank B, Dekkers-Bijma A M, Marquet R L, Lameris J S, Westbroek D L, Jeekel J: Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-αA (rIFNαA ).Cancer Immunol Immunother 21, 81 (1986). Wadler S, Schwartz E L, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik P H: Fluorouracil and recombinant alpha-2a- interferon: an active regimen against advanced colorectal carcinoma.J Clin Oncol 7, 1769 (1989). Neville A M, Gusterson B A: Monoclonal antibodies and human tumors; pathological and clinical aspects.Eur J Cancer Clin Oncol 21, 355 (1985). Herlyn D, Herlyn M, Ross A H, Ernst C, Atkinson B, Koprowski H: Efficient selection of human tumor growth-inhibiting monoclonal antibodies.J Immunol Methods 73, 157 (1984). Douillard J Y, Lehur P A, Vignoud J, Blottiére H, Maurel C, Thedrez P, Kremer M, Le Mevel B: Monoclonal antibodies specific immunotherapy of gastrointestinal tumors.Hvbridoma 5 (Suppl. 1), 139 (1986). Mellstedt H, Frödin J-E, Ragnhammar P, Masucci G, Shetye J, Christensson B, Biberfeld P, Makower J, Pihlstedt P, Cedermark B, Harmenberg U, Wahren B, Rieger Å, Magnusson I, Nathansson J, Erwald R: The clinical use of monoclonal antibodies, MAb 17- 1A, in the treatment of patients with metastatic colorectal carcinoma.Med Oncol Tumor Pharmacother 6, 99 (1989). Mellstedt H, Frödin J-E, Masucci G: Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma.Oncology 3, 25 (1989). Verrill H, Goldberg M, Rosenbaum R, Abbott R, Simunovic L, Steplewski Z, Koprowski H: Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarci- noma. A preliminary report.Hybridoma 5 (Suppl. 1), 175 (1986). Sears H F, Herlyn D, Steplewski Z, Koprowski H: Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adeno- carcinoma.Hvbridoma 5, 109 (1986). Magnani J L, Nilsson B, Brockhaus M,et al.: A monoclonal antibody defined antigen associated with gastro-intestinal cancer is a ganglioside containing sia- lylated lac tp-N-fu-copentaose II.J Biol Chem 257, 365 (1982). Ross A H, Herlyn D, Iliopoulos D,et al.: Isolation and characterization of a carcinoma-associated antigen.Biochem Biophys Res Commun 135, 297 (1986). Blaszczyk-Thurin M, Thurin J, Hindsgaul O,et al.: Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: isolation and characterization by mass spectrometry and NMR spectro- scopy.J Biol Chem 262, 372 (1987). Gold P, Freedom S O: Specific carcinoembryonic antigens of the human digestive system.J Exp Med 122 467 (1965). Lindholm L, Holmgren J, Svennerholm L,et al.: Monoclonal antibodies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides.Int Archs All Appl Immunol 71, 178 (1983). Adams D O, Hall T, Steplewski Z,et al: Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotype containing increased numbers of macrophages activated for distinctive form of antibody dependent cytolysis.Proc Natn Acad Sci 81, 3506 (1984). Shetye J, Frödin J-E, Christensson B,et al.: Immuno- histochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).Cancer Immunol Immunother 27, 154 (1988). Masucci G, Lindemalm C, Frödin J-E,et al.: Effect of human blood rnononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).Hvbridoma 7, 429 (1988). Frödin J-E, Lefvert A-K, Mellstedt H: Pharmacoki- netics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules.Cancer Res 50, 4866 (1990). Duvall E, Wyllie A H: Death and the cell.Immunol Today 7, 115 (1986). Wyllie A H, Kerr J F R, Currie A R: Cell death: the significance of apoptosis.Int Rev Cytol 68, 251 (1980). Trauth B C, Klas C, Peters A M J,et al.: Monoclonal antibody mediated tumor regression by induction of apoptosis.Science 245, 301 (1989). Anasetti C, Martin P J, Morishita Y,et al.: Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass.J Immunol 138, 2979 (1987). Ortaldo J R, Woodhouse C, Morgan A C,et al.: Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.J Immunol 138, 3566 (1987). Steplewski Z, Sun L K, Shearman C W,et al.: Biological activity of human-mouse IgG1 IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with anti- tumor specificity.Proc Natn Acad Sci USA 85, 4852 (1988). Fogler W E, Sun L K, Klinger M R,et al.: Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.Cancer Immunol Immunother 30, 43 (1989). Brown S L, Miller R A, Horning S J,et al.: Treatment of B cell lymphomas with anti-idiotype antibodies alone and combination with α-IFN.Blood 73, 651 (1989). Hale G, Clark M R, Marcus R,et al.: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibodies to Campath-1H.Lancet ii, 1394 (1988). Janson C H, Tehrani M J, Mellstedt H,et al.: Anti- idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody,in vitro effector functions and results of therapy.Cancer Immunol Immunother 28, 225 (1989). Mellstedt H, Frödin J-E, Ragnhammar P, et al.: Therapy of colorectal carcinoma with monoclonal antibodies (MAbl7-lA) alone and in combination with granulocyte monocyte-colony-stimulating factor (GM-CSF). Acta Oncologica (1991) (In press). Koprowski H, Herlyn D, Lubeck M,et al. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient?Proc Natn Acad Sci 81, 206 (1984). Jerne N K: Towards a network theory of the immune system.Ann Immunol 124, 373 (1974). Frödin J-E, Harmenberg U, Biberfeld P,et al.: Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas.Hybridoma 7, 309 (1988). Kedar E, Klein E: Cancer immunotherapy: Why are clinical results discouraging — can they be improved? Adv Cancer Res (1991) (In press). Parhar R S, Lala P K: Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity.Cell Immunol 93, 265 (1985). Berd D, Maguire H C Jr., Mastrangelo M J: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.Cancer Res 46, 2572 (1986). Douillard J Y, Lehur O A, Vignoud J,et al.: Monoclonal antibodies specific immunotherapy of gastrointestinal tumors.Hybridoma 5, 139 (1986). Markoe A M, Brady L W, Amendola B E,et al.: Treatment of gastrointestinal cancer using monoclonal antibodies, in Vaeth J M, Meyer J L (eds):Frontiers of Radiation Therapy and Oncology. The Present and Future Role of Monoclonal Antibodies in Management of Cancer, p. 214. Basel, Kager 24 (1990). Fogler W E, Klinger M R, Abraham K G,et al.: Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A anderen.Cancer Res 48, 6303 (1988). Masucci G, Wersäll P, Ragnhammar P,et al.: Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity.Cancer Immunol Immunother 29, 288 (1989). Masucci G, Wersäll P, Nielsen J,et al.: Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAbl7-lA: a combination of potential usefulness in tumor therapy.Hybridoma 8, 507 (1989). Wersäll P, Masucci G, Nielsen J,et al.: TNF-α and leukocyte α-IFN enhance IL-2 activated killer cell activity against tumor cells in the absence or presence of monoclonal antibodies.The Cancer Journal 3, 147 (1990). Masucci G, Ragnhammar P, Wersäll P,et al.: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2 induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (MAb 17- 1A).Cancer Immunol Immunother 31, 231 (1990). Wersäll P, Masucci G, Mellstedt H: Interleukin-4 (IL- 4) augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity.Cancer Immunol Immunother 33, 45 (1991). Weiner L M, Steplewski Z, Koprowski H,et al.: Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma.Hybridoma 5, 65 (1986). Weiner L M, Moldofsky P J, Gatenby R A,et al.: Antibody delivery and effector cell activation in a phase II trial of recombinant γ-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.Cancer Res 48, 2568 (1988). Santoli D, Clark S C, Kreider B L,et al.: Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor.J Immunol 141, 519 (1988). Hutchinson G H, Heinemann D, Ranson D L,et al.: Prognostic value ofin vitro tests of lymphocyte reactivity in colorectal carcinoma.J Exp Clin Cancer Res 2, 161 (1983). Umpleby H C, Heineman D, Symes M O,et al.: Expression of histocompatibility antigens and characterization of mononuclear cell infiltrates in normal and neoplastic colorectal tissue of humans.JNCI 74, 1161 (1985). Frödin J-E, Faxas M-E, Hagström B, et al.: Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1): an important antitumor- al effector function. Hybridoma (1991) (In press). Hoover H C Jr., Syrdyke M, Dangel R B,et al.: Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette Guérin Vaccine,Cancer Res 44, 1671 (1984). Hoover H C, Surdyke M G, Brandhorst J S,et al.: Five-year follow-up of a controlled trial of active specific immunotherapy in colorectal cancer. Abstract.Proc Am Soc Clin Oncol 9, 106 (1990). Bhattacharya-Chatterjee M, Pride M W, Seon B K,et al.: Idiotype vaccines against human T cell acute iymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti- idiotopes.J Immunol 139, 1354 (1987). Steinitz M, Tamir S, Frödin J-E,et al.: Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies.J Immunol 141, 3516 (1988). Steinitz M, Tamir S, Frödin J-E,et al.: Human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (MAbl7-lA) as an anti-tumor vaccine, in Börrebaeck C, Larrich J (eds):Therapeutic Monoclonal Antibodies., p. 159. London, Stockton Press (1990). Mellstedt H, Frödin J-E, Biberfeld P, et al.: Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to “the internal image of the antigen” (ab2). Int J Cancer (1991) (In press). Ferrone S, Chen Z J, Yang H,et al: Active specific immunotherapy with murine anti-idiotypic monoclonal antibodies which bear the internal image of the human high molecular weight-melanoma associated antigen (HMW-MAA). Abstract.Proc Ann Meet Am Assoc Cancer Res 31, 474 (1990). Rosenberg S A, Spiess P J, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes.Science 233, 1318 (1986). Sears H F, Herlyn D, Steplewski Z,et al.: Initial trial use of murine monoclonal antibodies and immunotherapeutic agents for gastrointestinal adenocarcinoma.Hybridoma 5, 109 (1986). LoBuglio A F, Saleh M N, Lee J,et al.: Phase I trial of multiple large doses of murine monoclonal antibody CO 17-1 A. I. Clinical aspects.J Natn Cancer Inst 80, 932 (1988). Goodman G E, Hellström I, Brodzinsky L,et al.: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer.J Clin Oncol 6, 1083 (1990). Dillman R O: Antibody therapy, in Oldham R K (ed):Principles of Cancer Biotherapy p. 291. New York, Raven Press (1987).